Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologySierra Health and Life Adakveo Coverage Update | O…
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0085L

    Adakveo (crizanlizumab-tmca) – Medical Benefit Coverage Criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0085L alerts

    Get alerted when Policy 2026D0085L changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical-benefit coverage of Adakveo (crizanlizumab-tmca) for members with sickle cell disease under UnitedHealthcare Commercial and Individual Exchange plans. It defines initial and continuation therapy criteria, exclusions, and applicable codes for providers and prior authorization processes.

    Policy Summary
    Payersierra health and life
    PolicyAdakveo (crizanlizumab-tmca) – Medical Benefit Coverage Criteria
    Policy CodePolicy 2026D0085L
    Change TypeTemplate update (no material clinical changes)
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, sickle cell diagnosis/genotype, VOC history, hydroxyurea status or intolerance, absence of chronic transfusions and concomitant voxelotor; ensure prescriber is or consulted with a hematologist.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥16min age
    ≥2VOCs for eligibility
    12 moauth period
    J0791HCPCS/J-code
    62.9% lowerrate reduction

    Coverage Criteria for Adakveo (crizanlizumab-tmca)

    Initial Therapy Criteria

    Covered when ALL of the following are met for Initial Therapy:

    Initial therapy core criteria

    • Age: Patient is 16 years of age or older>=16 years

      chunk 4

    • Diagnosis of a sickle cell disease (includes HbSS, HbSC, sickle beta0 thalassemia, sickle beta+ thalassemia)

      chunk 4

    • VOC/history criteria

      • Transition from Oxbryta: Patient is transitioning from treatment with Oxbryta (voxelotor) to Adakveo

        chunk 4

      • VOC frequency: Patient has previously experienced 2 or more sickle cell-related vaso-occlusive crises within the previous 12 months>=2 in 12 months

        chunk 4

    • Hydroxyurea status

      • On hydroxyurea: Patient is currently receiving hydroxyurea therapy

        chunk 5

      • Hydroxyurea failure/intolerance: History of treatment failure, intolerance, or contraindication to hydroxyurea therapy

        chunk 5

      • Provider attestation: Provider attests that the patient is not an appropriate candidate for hydroxyurea based on genotype (patient does not have HbSS or sickle beta0 thalassemia)

        chunk 5

    • No chronic transfusion: Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy

      chunk 5

    • No concomitant voxelotor: Patient is not receiving concomitant Oxbryta (voxelotor) therapy

      chunk 5

    • Prescriber specialty: Adakveo is prescribed by, or in consultation with, a hematologist or other specialist with expertise in the diagnosis and management of sickle cell disease

      chunk 5

    Continuation Therapy Criteria

    Covered when ALL of the following are met for Continuation Therapy:

    Continuation therapy core criteria

    • Diagnosis of a sickle cell disease (includes HbSS, HbSC, sickle beta0 thalassemia, sickle beta+ thalassemia)

      chunk 8

    • Clinical benefit: Patient has experienced a reduction in sickle cell-related vaso-occlusive crises and/or a decrease in severity of vaso-occlusive crises from pretreatment baseline while on Adakveo

      chunk 8

    • No chronic transfusion: Patient is not receiving concomitant chronic, prophylactic blood transfusion therapy

      chunk 8

    • No concomitant voxelotor:

    Not Proven / Not Medically Necessary

    Not proven/Not medically necessary indications

    • Pediatric <16: Pediatric patients less than 16 years of age with sickle cell disease

      chunk 9

    • Myelofibrosis: Use of Adakveo for myelofibrosis

      chunk 9

    Clinical evidence and guideline considerations

    Clinical evidence and guideline considerations summarized:

    Crizanlizumab efficacy: High‑dose crizanlizumab prolonged median time to first and second VOCs (4.07 vs 1.38 months and 10.32 vs 5.09 months, respectively), showed a 62.9% lower rate of uncomplicated crises per year versus placebo (median 1.08 vs 2.91), with benefit evident within 2 weeks and maintained over a 52‑week treatment phase; no significant differences were observed in markers of hemolysis or days hospitalized.

    chunk 18

    Hydroxyurea evidence: The MSH randomized trial (adults with ≥3 VOCs in the prior year) demonstrated hydroxyurea reduced frequency of painful episodes, acute chest syndrome events, transfusions, and hospitalizations; median crises 2.5 vs 4.5 per year and longer time to first and second crises, supporting FDA approval for clinically severe SCA in adults.≥3 VOCs in prior year

    chunks 19,20

    Guideline recommendations: NHLBI 2014 recommends hydroxyurea for adults with three or more moderate‑to‑severe pain crises in 12 months and for other specified indications, recommends established prescribing and monitoring protocols, and advises offering hydroxyurea to children ≥9 months regardless of severity.

    Adakveo (crizanlizumab-tmca) is not proven or medically necessary for use in pediatric patients who are less than 16 years of age. The policy explicitly lists pediatric patients <16 with sickle cell disease as an exclusion for coverage, and use in this population does not meet the criteria for medical necessity under this policy.

    The safety and efficacy of Adakveo in pediatric patients younger than 16 years have not been established. The FDA-labeled indication for Adakveo applies to adults and pediatric patients aged 16 years and older, and the policy relies on this limitation when determining that use below age 16 is not supported by available evidence.

    Reiterating coverage limits: Adakveo is not proven or medically necessary for pediatric patients under 16 years of age, and the policy also identifies use for myelofibrosis as not medically necessary. The document notes that the FDA indication is for patients aged ≥16 years, and safety/efficacy have not been established for those younger than 16.

    Applicable Codes

    Applicable HCPCS/CodesHCPCS
    J0791Injection, crizanlizumab-tmca, 5 mg
    Applicable ICD-10 Codes (sickle cell disease and variants)ICD-10
    D57.0Hb-SS disease with crisis
    D57.00Hb-SS disease with crisis, unspecified
    D57.01Hb-SS disease with acute chest syndrome
    D57.02Hb-SS disease with splenic sequestration
    D57.03Hb-SS disease with cerebral vascular involvement
    D57.04Hb-SS disease with dactylitis
    D57.09Hb-SS disease with crisis with other specified complication
    D57.1Sickle-cell disease without crisis
    D57.2Sickle-cell/Hb-C disease
    D57.20Sickle-cell/Hb-C disease without crisis
    1–10 of 52
    1/6
    Number of VOCs in prior 12 months — eligibility threshold
    Eligibility threshold>= 2 sickle cell–related vaso‑occlusive crises (VOCs) within the previous 12 months
    Alternate qualifying conditionTransitioning from Oxbryta (voxelotor) to Adakveo
    Age requirement contextApplies as part of initial therapy criteria for patients 16 years of age or older

    Provider Action Items, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Adakveo (crizanlizumab-tmca). Initial authorization will be for no more than 12 months and dosing must follow FDA-approved labeling. Adakveo maintenance/continuation authorizations are also limited to no more than 12 months with maintenance dosing per FDA labeling.

    • Prior authorization required
    • Initial and reauthorization period: ≤ 12 months
    • Dosing must follow FDA-approved labeling
    Documentation Required

    Required Clinical Documentation

    Providers must document clinical criteria to support medical necessity. Required documentation includes patient age, documented diagnosis/genotype of sickle cell disease, number of vasoocclusive crises (VOCs) in the prior 12 months or documentation of transition from voxelotor, hydroxyurea treatment status (on hydroxyurea, history of failure/intolerance/contraindication, or provider attestation that patient is not an appropriate candidate), and whether the patient is receiving chronic prophylactic transfusions or concomitant voxelotor therapy. Adakveo must be prescribed by or in consultation with a hematologist or other specialist with expertise in sickle cell disease.

    Background on Condition and Therapy

    Sickle cell disease (SCD) is an inherited hemoglobin disorder in which abnormal hemoglobin polymerization causes red blood cells to sickle, resulting in hemolysis, inflammation, and microvascular occlusion. These pathophysiologic processes produce recurring vaso-occlusive crises (VOCs), acute pain episodes, and progressive end-organ injury. Therapies that interrupt the cellular interactions and adhesion events that contribute to vaso‑occlusion can reduce VOC frequency; Adakveo (crizanlizumab‑tmca) is a monoclonal antibody directed against P‑selectin that aims to block those interactions. Clinical trials (for example, SUSTAIN) demonstrated that crizanlizumab reduced the rate of VOCs and prolonged time to first and second crises compared with placebo over a 52‑week treatment period.

    Definitions

    Vaso-occlusive crisis (VOC) — definition including facility visit and analgesic requirements
    Core VOC definitionAn acute episode of pain attributed to vaso‑occlusion requiring a medical facility visit and oral or parenteral opioids, or parenteral NSAIDs
    Events included as VOCsAcute chest syndrome, hepatic sequestration, splenic sequestration, and priapism when they require a visit to a medical facility
    Context from clinical trial endpointPrimary efficacy outcome in SUSTAIN defined VOCs as episodes leading to a healthcare visit; trial eligibility required history of 2–10 VOCs in prior 12 months
    Vaso‑occlusive crisis (VOC) — additional VOC definition entry
    Healthcare‑visit requirementVOC is defined by requirement for a medical facility visit (used as the trial primary outcome measure)
    Analgesic requirement
    Policy Summary
    Payersierra health and life
    PolicyAdakveo (crizanlizumab-tmca) – Medical Benefit Coverage Criteria
    Policy CodePolicy 2026D0085L
    Change TypeTemplate update (no material clinical changes)
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, sickle cell diagnosis/genotype, VOC history, hydroxyurea status or intolerance, absence of chronic transfusions and concomitant voxelotor; ensure prescriber is or consulted with a hematologist.
    SourceLink
    On This Page
    Coverage Criteria for Adakveo (crizanlizumab-tmca)Applicable CodesProvider Action Items, Prior Authorization, and DocumentationBackground on Condition and TherapyDefinitions
    Patient is not receiving concomitant Oxbryta (voxelotor) therapy

    chunk 8

  1. Prescriber specialty: Adakveo is prescribed by, or in consultation with, a hematologist or other specialist with expertise in the diagnosis and management of sickle cell disease

    chunk 8

  2. Dosing: Adakveo maintenance dosing is in accordance with the United States Food and Drug Administration approved labeling

    chunk 8

  3. Authorization period: Reauthorization will be for no more than 12 months

    chunk 8

  4. chunk 21

    • Document age (must be ≥ 16 years)
    • Document sickle cell diagnosis and genotype
    • Document VOC count in prior 12 months or transition from Oxbryta (voxelotor)
    • Document hydroxyurea use or history of failure/intolerance/contraindication or provider attestation
    • Document absence of chronic prophylactic transfusion and absence of concomitant voxelotor
    • Document that prescribing clinician is a hematologist or specialist experienced in sickle cell disease
    Note

    Policy and Benefit Plan Precedence

    Coverage decisions should reference the member-specific benefit plan document first. This UnitedHealthcare Medical Benefit Drug Policy provides standard plan guidance but the member-specific benefit plan governs in the event of a conflict. Also check applicable federal or state mandates prior to authorization.

    • Reference the member-specific benefit plan document when deciding coverage
    • UnitedHealthcare Medical Benefit Drug Policy is interpretive for UnitedHealthcare standard plans and may be superseded by member-specific terms
    • Check applicable federal/state mandates before applying policy
    Documentation Required

    Hydroxyurea Requirement / Consideration

    Hydroxyurea use is expected unless there is documentation of failure, intolerance, or contraindication, or the provider attests the patient is not an appropriate candidate (e.g., non-HbSS or non–sickle beta 0 thalassemia genotypes). Concurrent hydroxyurea is acceptable and may be required as part of criteria.

    • Patient is currently receiving hydroxyurea therapy; or
    • Patient has history of hydroxyurea treatment failure, intolerance, or contraindication; or
    • Provider attests patient is not an appropriate candidate for hydroxyurea (document rationale)
    Note

    Professional Society Guidance

    Professional society guidance (NHLBI) supports use of hydroxyurea in adults with SCA who have ≥3 VOCs/year and recommends established prescribing and monitoring protocols. For patients not demonstrating response to hydroxyurea, consultation with a sickle cell expert is advised. These recommendations should inform treatment decisions and documentation.

    • NHLBI recommends hydroxyurea for adults with ≥3 VOCs/year (strong recommendation)
    • Use established prescribing and monitoring protocols for hydroxyurea
    • Consult a sickle cell expert when clinical response to hydroxyurea is inadequate
    Denial Risk

    Clinical Exclusions / Contraindication Triggers

    Clinical exclusion and contraindication triggers that may lead to denial include: patient age < 16 years; concomitant chronic prophylactic blood transfusion therapy; concomitant Oxbryta (voxelotor) therapy; diagnoses for which Adakveo is not proven (e.g., myelofibrosis); and lack of required documentation (age, diagnosis/genotype, VOC history, hydroxyurea status, specialist involvement).

    • Age < 16 years — not eligible
    • Concomitant chronic prophylactic blood transfusion therapy — exclusion
    • Concomitant Oxbryta (voxelotor) therapy — exclusion
    • Use for diagnoses without demonstrated benefit (e.g., myelofibrosis) — exclusion
    • Insufficient clinical documentation to meet criteria — potential denial
    Note

    UnitedHealthcare Medical Benefit Drug Policy Notice

    This policy is a UnitedHealthcare Medical Benefit Drug Policy intended to assist in interpreting UnitedHealthcare standard benefit plans (including Commercial and Individual Exchange where applicable). It is informational and does not constitute medical advice. Before applying this policy, review the member-specific benefit plan document and applicable mandates.

    • UnitedHealthcare Medical Benefit Drug Policy — interpretive guidance for standard plans
    • Applies to UnitedHealthcare Commercial and Individual Exchange benefit plans as noted in policy history
    • Member-specific benefit plan governs in event of conflict
    Management includes oral or parenteral opioids, or parenteral NSAIDs as part of the definition of a VOC requiring a visit
    Regulatory noteFDA indication: Adakveo is indicated to reduce VOC frequency in patients aged 16 years and older; safety/efficacy not established <16 years